2026-01-02 - Analysis Report
Okay, here's a comprehensive analysis of Teladoc Health Inc. (TDOC) based on the provided data, structured as requested:

**1) Return Rate Comparison (TDOC vs. S&P 500)**

*   **TDOC Company Overview:** Teladoc Health Inc. is a telehealth company that offers virtual medical care services.

*   **Simple Numbers:**
    *   TDOC Cumulative Return: -65.24%
    *   VOO (S&P 500) Cumulative Return: 105.07%
    *   Divergence: -170.3
    *   Relative Divergence: 0.4

*   **Analysis:** TDOC has significantly underperformed the S&P 500.  The negative cumulative return indicates a substantial loss of investment value compared to the positive return of the S&P 500. The divergence is substantial. The relative divergence of 0.4 suggests the current divergence is near the lower end of its historical range.

*   **Alpha, Beta Analysis:**

    | Year       | CAGR    | MDD     | Alpha    | Beta  | Cap(B) |
    |------------|---------|---------|----------|-------|--------|
    | 2016-2018  | 205.0%  | 69.5%   | 176.0%   | 1.7   | 8.8    |
    | 2017-2019  | 319.0%  | 83.9%   | 277.0%   | 1.8   | 14.9   |
    | 2018-2020  | 435.0%  | 83.9%   | 402.0%   | 0.7   | 35.5   |
    | 2019-2021  | 43.0%   | 81.5%   | -33.0%   | 0.5   | 16.3   |
    | 2020-2022  | -77.0%  | 95.5%   | -96.0%   | 0.8   | 4.2    |
    | 2021-2023  | -92.0%  | 95.5%   | -120.0%  | 1.9   | 3.8    |
    | 2022-2024  | -88.0%  | 90.2%   | -118.0%  | 1.9   | 1.6    |
    | 2023-2025  | -76.0%  | 88.4%   | -144.0%  | 1.7   | 1.2    |

    *   **CAGR:** Shows a massive drop in growth from the 2018-2020 period to the current period. The company has experienced a significant decline in annual growth rates.
    *   **MDD (Maximum Drawdown):** Consistently high MDD values indicate substantial risk and volatility. The stock's value has experienced significant peak-to-trough declines.
    *   **Alpha:** The Alpha figures are concerning. Early periods show strong outperformance, but recent years show substantial negative Alpha, indicating significant underperformance compared to the market, even when accounting for the stock's beta.
    *   **Beta:** The Beta values indicate the stock's volatility relative to the market. Beta has recently increased significantly, suggesting the stock is now more volatile than the market. A beta near 1.8 implies it is roughly 80% more volatile than the S&P 500.
    *   **Cap(B):** The market capitalization has decreased from 8.8B to 1.2B from 2016 to 2025, highlighting the substantial decline in the company's value.

**2) Recent Stock Price Fluctuations**

*   **Simple Numbers:**
    *   Close: 7.0
    *   Last-market: price 7.0, previousClose 7.0, change 0.0
    *   5-day SMA: 7.06
    *   20-day SMA: 7.358
    *   60-day SMA: 7.7868

*   **Analysis:** The stock price is below all its moving averages (5-day, 20-day, and 60-day). This suggests a short-term and medium-term downward trend. The last-market data shows no price change, suggesting the stock price has been stagnating.

**3) Indicators Analysis**

*   **Simple Numbers:**
    *   MRI (Market Risk Indicator): 0.9 (High Investment Recommended)
    *   RSI: 23.26
    *   PPO: -0.41
    *   Hybrid Signal: cash_0%_Buy 100% of cash (133 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
    *   Recent (20 days) relative divergence change: 0.4 (+): 단기상승 (Short-term increase)
    *   Expected Return (%): 0.0

*   **Analysis:**
    *   **MRI:** An MRI of 0.9 suggests a high investment recommendation according to the given scale. This might be contradictory to other indicators suggesting the stock is risky. It is essential to use a holistic approach and not rely on a single indicator.
    *   **RSI:** An RSI of 23.26 indicates the stock is oversold. This *could* suggest a potential for a price rebound, but it's not a guarantee.
    *   **PPO:** A negative PPO (-0.41) indicates that the short-term moving average is below the long-term moving average, confirming a downtrend, but only slightly.
    *   **Hybrid Signal:** The signal to buy 100% of cash is based on the high MRI.
    *   **Recent Relative Divergence Change:** The recent increase in relative divergence is a sign of a short-term upward trend.
    *   **Expected Return:** The 0.0% expected return is concerning. It suggests that, even with a long-term investment horizon, the model does not foresee significant gains.

**4) Recent News & Significant Events**

*   **Key Takeaways from Headlines:**
    *   **Competition:** The news articles highlight competition from other telehealth stocks (HIMS).
    *   **Volatility:** The stock is described as volatile.
    *   **Mixed Sentiment:** The news is mixed, with some articles suggesting to "Forget Teladoc" in favor of alternatives, while others discuss potential reasons for price increases.
    *   **Fading Hope:** Some articles point towards declining confidence in the stock's prospects.

**4-2) Analyst Opinions**

*   **Simple Numbers:**
    *   Consensus: Neutral to Negative (Mean not provided, but described as 1=Strong Buy, 5=Sell)
    *   Opinions: 22 Analysts
    *   Target Price (Avg/High/Low): 9.18 / 12.00 / 7.00
    *   Recent Rating Changes: Not provided.

*   **Analysis:** Analyst opinions are mixed, as there are 22 opinions with Target Price set to be around 9.18.

**5) Recent Earnings Analysis**

*   **Table:**

    | 날짜       | EPS    | 매출     |
    |------------|--------|----------|
    | 2025-10-30 | -0.28  | 0.63 B$  |
    | 2025-07-30 | -0.19  | 0.63 B$  |
    | 2025-05-01 | -0.53  | 0.63 B$  |
    | 2024-10-31 | -0.19  | 0.64 B$  |
    | 2025-10-30 | -0.19  | 0.64 B$  |

*   **Analysis:**
    *   The company consistently reports negative EPS (Earnings Per Share). This indicates the company is not profitable.
    *   Revenue is relatively stable around $0.63-0.64 billion per quarter. The stable revenue isn't enough to offset costs and generate profit.

**6) Financial Information**

*   **Revenue and Profitability:**

    | Quarter      | Revenue   | Profit Margin |
    |--------------|-----------|---------------|
    | 2025-09-30   | $0.63B    | 70.12%        |
    | 2025-06-30   | $0.63B    | 69.85%        |
    | 2025-03-31   | $0.63B    | 68.73%        |
    | 2024-12-31   | $0.64B    | 70.50%        |
    | 2024-09-30   | $0.64B    | 71.94%        |

    *   **Analysis:**
        *   Revenue is consistent, which is a positive sign.
        *   Profit margins are high (around 70%), suggesting that while Teladoc is good at controlling the direct costs of providing its services, other factors are eating into the profitability, such as overhead, marketing, or interest expenses.

*   **Capital and Profitability:**

    | Quarter      | Equity    | ROE       |
    |--------------|-----------|-----------|
    | 2025-09-30   | $1.39B    | -3.56%    |
    | 2025-06-30   | $1.42B    | -2.30%    |
    | 2025-03-31   | $1.43B    | -6.52%    |
    | 2024-12-31   | $1.49B    | -3.25%    |
    | 2024-09-30   | $1.51B    | -2.21%    |

    *   **Analysis:**
        *   Equity is decreasing, which is a concern. It suggests that the company is losing assets faster than it is generating them.
        *   ROE (Return on Equity) is consistently negative. This further confirms the company's lack of profitability.

**7) Comprehensive Analysis**

*   **Summary:**
    *   TDOC has significantly underperformed the market (S&P 500) over the past several years.
    *   The stock is in a downtrend, trading below its moving averages.
    *   Indicators like RSI suggest the stock is oversold, potentially signaling a short-term bounce, but this is not a guarantee.
    *   The company consistently reports negative EPS and negative ROE, indicating a lack of profitability.
    *   Equity is decreasing, which is a warning sign.
    *   The high profit margin shows that there might be a possibility if they fix overall costs, but at the moment, it is not enough to offset costs and generate profit.
    *   Recent news headlines are mixed, with concerns about competition and fading investor confidence.
    *   Analysts appear to have a neutral to negative outlook on the stock, with target prices only slightly above the current price.

*   **Overall Assessment:** Based on the provided data, investing in TDOC appears risky. The negative profitability, decreasing equity, significant underperformance compared to the S&P 500, and mixed news sentiment all point to substantial challenges for the company. While an oversold RSI might suggest a short-term trading opportunity, the fundamental issues suggest caution for long-term investors.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.